




Supplementary Figure S1. YAP represses the transcriptional activity of p53. H1299 cells were transfected with a p53 reporter plasmid, *p21*-promoter Luc and pCMV/ β -gal in combination with the indicated constructs. After 24 h, luciferase activity in cell lysates was measured and normalized with β -gal activity. Experiments were performed in triplicate, and data are represented as mean activation fold \pm S.D. Significant differences are indicated as ** $p < 0.01$.




Supplementary Figure S2. MCF7 cells were cultured at low density (0.5×10^5 cells/well) or high density (1.0×10^6 cells/well). After 24 h, cells were treated with 10 nM actinomycin D (Act D) for 4 h. Cell lysates were analyzed by immunoblotting using the indicated antibodies.


(A)**(B)**

Supplementary Figure S3. MCF7 cells were transfected with the indicated siRNAs. After 48 h, cells were treated with 10 μ M Nutlin-3 for 48 h. Quantitation of apoptotic cell death was examined by Annexin V staining. Shown are average results from three experiments (A). Cells were then stained for senescence-associated β -gal (SA- β -gal). The bar graph shows the percentage of SA- β -gal-positive cells in the indicated culture (n=3) (B). Significant differences are indicated as **p<0.01 and *p<0.05.

(A)



(B)



Supplementary Figure S4. TIG1 cells or TIG1/shp53 cells expressing Tetracycline-inducible p53 (Teton-p53) were infected with lentiviral vectors containing shRNA for *TAZ* (shTAZ) or control (shCtrl) in the presence (Teton-p53) or absence of doxycycline (1 μ g/ml) for 7 d. Cells were then stained for senescence-associated β -gal (SA- β -gal). The bar graph shows the percentage of SA- β -gal-positive cells in the indicated culture (n=3) (A). The expression of each gene was assessed by qPCR, and the mRNA levels of the indicated genes were normalized with β -actin mRNA. Result was shown as means \pm S.D. (n=3) (B). Significant differences are indicated as **p<0.01.